CU researchers have developed a human thyroid cancer cell line with the HRAS Q61R mutation. The cell line, called CUTC61, was derived from a 72-year-old female patient with metastatic follicular thyroid cancer (FTC) and was developed to study tumor progression and response to therapy. The CUTC61 cells can be used as in vitro cultured cell and patient-derived xenograft (PDX) models. Thus, this creates a novel, patient-derived cell line to study advanced thyroid cancer.
Schweppe RE, Pozdeyev N, Pike LA, et al. Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers. Mol Cancer Res. 2019. pii: molcanres.1026.2018. doi: 10.1158/1541-7786.MCR-18-1026.